MEMO THERAPEUTICS
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
MEMO THERAPEUTICS
Social Links:
Industry:
Biotechnology Collaboration
Founded:
2012-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.memo-therapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+41 44 515 91 40
Email Addresses:
[email protected]
Total Funding:
59.15 M USD
Technology used in webpage:
IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online Office 365 Mail ReCAPTCHA
Similar Organizations
Adrestia Therapeutics
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Amsterdam Scientific Instruments
Amsterdam Scientific Instruments specializes in the fields of neutron detection, electron imaging, and X-ray detector technology.
Anocca AB
Anocca AB provides services like Biotechnology, Immunotherapeutics, Drug Discovery, Drug Development, Immunology.
Aphea.Bio
Aphea.Bio offers research and development in the areas of bioinsecticides and bioherbicides.
BIOT
BIOT is dedicated to research and innovation in the field of microbiology and biotechnology.
Bluu Seafood
Bluu Seafood Provides Sea Food Manufacturing Services.
Celtic Renewables
Celtic Renewables is a biofuel startup focused on the renewable energy and whisky sector.
Domainex
A fully integrated drug discovery service company.
EMMAC Life Sciences
EMMAC is a medical cannabis company that works to join together the latest science and research with cutting-edge cultivation.
ETHRIS
ETHRIS is a technical innovator in the emerging field of mRNA therapeutics and LNP delivery.
Evariste Technologies
Biotech using quantitative modelling to make drug discovery more efficient
genomes.io
genomes.io is a human genome is the blueprint to what makes you who you are.
Hoxton Farms
Based in London, UK, Hoxton Farms is growing cultivated fat as an ingredient for the meat alternatives industry.
IMVAQ Therapeutics
Imvaq Therapeutics is an innovative cancer immunotherapy company.
Infinited Fiber Company
Infinited Fiber Company is on a mission to make circular fashion and textiles an everyday reality
KYMIRA Sport
KYMIRA Sport is developing a range of performance and recovery enhancing sportswear.
Leucid Bio
Leucid is progressing novel cart therapies that produce a better and more durable response.
Mnemo Therapeutics
Mnemo Therapeutics specializes in biotechnology and life science.
ORF Genetics
ORF Genetics is an innovative company that is committed to economically viable and enabling solutions.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
PATS
PATS is an Indoor Drone Solutions enables greenhouse farmers to significantly reduce and eliminate flying insect pest populations
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Telomere Therapeutics
Telomere Therapeutics is a University of Barcelona spinoff developing telomerase gene therapy to treat pulmonary fibrosis
Current Advisors List
Current Employees Featured
Founder
Investors List
Verve Ventures
Verve Ventures investment in Series B - Memo Therapeutics
Fresenius Medical Care
Fresenius Medical Care investment in Series B - Memo Therapeutics
Zürcher Kantonal Bank
Zürcher Kantonal Bank investment in Series B - Memo Therapeutics
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series B - Memo Therapeutics
Adjuvant Capital
Adjuvant Capital investment in Series B - Memo Therapeutics
GF Group Holding
GF Group Holding investment in Series B - Memo Therapeutics
Swisscanto Private Equity
Swisscanto Private Equity investment in Series B - Memo Therapeutics
Federal Office of Public Health (FOPH) Switzerland
Federal Office of Public Health (FOPH) Switzerland investment in Grant - Memo Therapeutics
Bernina BioInvest
Bernina BioInvest investment in Series B - Memo Therapeutics
Redalpine
Redalpine investment in Series B - Memo Therapeutics
Official Site Inspections
http://www.memo-therapeutics.com
- Host name: 185-151-30-220.ptr4.stackcp.net
- IP address: 185.151.30.220
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Memo Therapeutics"
About Us - Memo Therapeutics AG
Prior to joining Memo Therapeutics AG, he was Deputy CFO and Head of M&A and Group Controlling at ORIOR (SWX:ORON), with previous roles at Capvis Equity Partners as …See details»
Memo Therapeutics - Crunchbase Company Profile
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB platform creates a recombinant in vitro copy …See details»
Memo Therapeutics AG - Swiss Biotech
Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the …See details»
Mnemo Tx | Biotech | Paris : Developing a robust, tumour-specific ...
Mnemo Therapeutics is a Paris-based biotechnology company driven to create powerful immunotherapies by improving the body’s ability to detect and eradicate cancer. top of page. …See details»
Memo Therapeutics - PitchBook
Kinled Holding, Kurma Partners, Pureos Bioventures, Ysios Capital, and Adjuvant Capital are 5 of 19 investors who have invested in Memo Therapeutics. Who …See details»
Memo Therapeutics AG - Company Profile and News
Memo Therapeutics AG operates as a biotechnology company. The Company specializes in antibody discovery and human immune repertoire analysis for the treatment of immuno …See details»
Memo Therapeutics AG - Venturelab
Dec 20, 2012 Memo Therapeutics gets CHF 10.5 million from the Swiss government to clinically develop their antibody against COVID-19 (venturelab.swiss) 13.12.2021. Federal government signs four contracts for …See details»
Memo Therapeutics AG Secures $20 Million in Series C Funding for ...
Jan 20, 2025 Memo Therapeutics AG (MTx), a pioneering late-stage biotech firm based in Schlieren, Zurich, has successfully secured a notable financing round, raising a remarkable …See details»
Memo Therapeutics - VentureRadar
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening …See details»
Memo Therapeutics AG | Best-in-Class Therapeutic …
Memo Therapeutics AG is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer. Our lead program, potravitug, currently in Phase II development, is the …See details»
Interview Erik van den Berg - verve.vc
Mar 19, 2024 Memo Therapeutics AG (Memo) was founded in 2012 with technology that originated at the Swiss Federal Institute of Technology in Zurich (ETH). Memo is focused on developing best-in-class therapeutic antibodies …See details»
CMV (Memo Therapeutics) - Drug Targets, Indications, Patents
May 7, 2025 CMV (Memo Therapeutics), Initially developed by Memo Therapeutics AG, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Infectious Diseases, Active …See details»
Ono Enters a Drug Discovery Collaboration Agreement with Memo ...
Nov 1, 2022 About Memo Therapeutics AG Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery …See details»
Memo Therapeutics AG - Company Profile - leadsontrees.com
Memo Therapeutics AG. Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development …See details»
Latest news - Memo Therapeutics
Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat …See details»
Memo Therapeutics AG Appoints Paul Carter as Chairperson
Jul 8, 2024 Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to …See details»
Contact Us - Memo Therapeutics AG
Memo Therapeutics AG Wagistrasse 27 8952 Schlieren / Zurich Switzerland. [email protected] +41 44 515 91 40; US office. Memo Therapeutics US, Inc. 6475 Rock Ridge …See details»
Careers - Memo Therapeutics AG
The Memo Therapeutics AG team is always on the lookout for shapes around the world that resemble antibodies. They take this pursuit seriously and even hold annual competitions within …See details»
Memo pushes kidney drug to phase 3 despite primary endpoint miss
6 days ago A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of setbacks in the indication. But the Swiss biotech saw …See details»
Memo Therapeutics AG Announces Phase II Trial ... - The Manila …
6 days ago Memo Therapeutics AG ("MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class …See details»